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Background: Human papillomavirus (HPV) variants differ in their biological and chemical properties, and therefore,
may present differences in pathogenicity. Most authors classified variants based on the phylogenetic analysis of L1
region. Nevertheless, recombination in HPV samples is becoming a usual finding and thus, characterizing genetic
variability in other regions should be essential.
Objectives: We aimed to characterize the genetic variability of HPV 18 in 5 genomic regions: E6, E7, E4, L1 and the
Upstream Regulatory Region (URR), working with both single infection and multiple HPV infection samples.
Furthermore, we aimed to assess the prevalence of HPV 18 variants in our region and look for possible existence of
recombination as well as analyze the relationship between these variants and the type of lesion.
Methods: From 2007 to 2010, Clinical Microbiology and Infection Control Department analyzed 44 samples which
were positive for HPV 18. Genetic variability was determined in PCR products and variants were assigned to
European, Asian-amerindian or African lineage. Recombination and association of variants with different types of
lesion was studied.
Results: Genetic analysis of the regions revealed a total of 56 nucleotide variations. European, African and
Asian-amerindian variants were found in 25/44 (56.8%), 10/44 (22.7%) and 5/44 (11.4%) samples, respectively. We
detected the presence of recombinant variants in 2/44 (4.5%) cases. Samples taken from high-grade squamous
intraepithelial lesions (H-SIL) only presented variants with specific-african substitutions.
Conclusions: Multiple HPV infection, non-european HPV variants prevalence and existence of recombination are
considered risk factors for HPV persistence and progression of intraepithelial abnormalities, and therefore, should be
taken into consideration in order to help to design and optimize diagnostics protocols as well as improve
epidemiologic studies.
Our study is one of the few studies in Spain which analyses the genetic variability of HPV18 and we showed the
importance of characterizing more than one genomic region in order to detect recombination and classify HPV
variants properly.
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Based on the epidemiologic classification in terms of
their risk to induce cervical cancer, human papilloma-
viruses (HPV) can be divided into 3 groups: “high-risk”
genotypes associated with a greater risk of developing
cancer, “low-risk” genotypes associated with low grade
cell changes or benign epithelium proliferations in the
genital area, but not with cancer, and “probable high-
risk” genotypes from which there is not enough data
about their relationship with cervical cancer to classify
them [1].
About 15 genotypes are classified as high-risk types,
and two of them (16 and 18) cause over 70% of all
cervical cancer cases [2,3]. Nucleotide variability of
these genotypes has been largely studied and different
molecular variants were described [4,5]. These variants
differ in their biological and chemical properties
[6–8], and therefore, may become an important risk
factor in cervical cancer due to possible differences in
pathogenicity.
Most authors classified variants based on the phylogene-
tic analysis of one genomic region nucleotide variations
[9]. Nevertheless, some publications have confirmed the
presence of recombination in HPV samples [10,11]. This
event may occur due to a homologous recombination or
to a repeated infection of the same HPV genotype but dif-
ferent variant and it is more often found since coinfections
with more than one HPV type are becoming a usual find-
ing [12–14]. Therefore, it should be essential to determine
HPV variants analyzing different genomic regions and
multiple infections.
There are very few epidemiological national studies in
Spain and all of them refer to HPV 16 which is the most
investigated HPV type worldwide. However, there is no
previous national work related to HPV 18 nucleotide
variability, which is the second most prevalent HPV
genotype found in cervical cancer.
The aim of the present study was: i) to characterize
the genetic variability of HPV 18 in 5 genomic regions:
E6, E7, E4, L1 and the Upstream Regulatory Region
(URR), working with both single infection and multiple
HPV infection samples, ii) assess the prevalence of HPV
18 variants in our region and look for existence of re-
combination, and iii) analyze the relationship between
variants and types of lesion.
Results
Samples collected
Since 2007 to 2010, a total of 1085 positive samples for
HPV were received and analyzed. HPV 18 was detected
in 65 samples (6%). Forty-four patients consented to
have their samples analyzed and studied, so this study
was based on their samples: 10 single HPV infections
(22.7%) and 34 multiple HPV infections (77.3%).We were able to amplify HPV DNA in 43/44 samples
for E6 region, 41/44 for E7, 35/44 for E4, 43/44 for L1
region and 44/44 for URR region. All PCR products
were sequenced and sequences from each region were
submitted to GenBank.
Nucleotide variations
Variant distribution was determined through E6, E7, E4,
L1 and URR sequences. Genetic analysis of the regions
revealed a total of 56 nucleotide variations (Figure 1).
In the E6 gene nine nucleotide variations were
detected. Six of them were specific to the African
lineage: T317C (6/10 African variants), T251C (9/10),
A548G, G266A and G374A (present in all African iso-
lates) and C342T (5/10 African variants) which lead to a
non-synonymous amino acid alteration His/Tyr. A non-
synonymous substitution T318C (Tyr/His) was found to
be specific to the European lineage (2/25 European iso-
lates), while the synonymous substitution C549A was
detected among the three different branches (35/43
sequenced E6 amplimers). In our study, C287G was
observed in all HPV 18 isolates.
E7 gene genetic variability analysis revealed five
nucleotides substitutions. Three nucleotide variations
were specific for the African lineage: C665T (3/10 African
variants), C593T (His/Tyr), C640C and T864G (Asn/Ser).
All of them but C665T and T864G were present in all
African variants. One synonymous substitution (C751T)
was detected in both European and Asian-amerindian
isolates (26/34 non-African variants).
E4 gene analysis presented most nucleotide variations
(17 substitutions) and almost half of them (8/17) lead to
amino acid changes. All African variants showed 4 non-
synonymous substitutions (C3558A His/Gln, C3578T
Ser/Leu, A3586C Ser/Arg and T3593G Ile/Ser), one
synonymous variation (T3534C) and a deletion of 6
amino acids (3627–3632). European variants showed 4
specific non synonymous substitutions G3482A (Ser/
Asn, 3/25 isolates), T3563A (Leu/Gln, 4/25), C3617T
(Ser/Leu, 4/25) and C3630G (His/Gln, all European iso-
lates). Two non-synonymous substitutions were also
detected in two European isolates: T3492A and C3615T.
L1 gene and URR sequence analysis demonstrated the
presence of substitutions C6842G and T7592C in all our
isolates.
Most nucleotide variations found in our study have
been already described in literature except for T318C,
C665T, C3615T, C3617T, G6897A, G6993A, A7000T/C,
T7001C, T7007G and T7765G. Only substitutions in
positions 318 and 3617 lead to amino acid changes (Tir/
His and Ser/Leu, respectively). T318C substitution was
present in 2 European isolates whereas C3617T nucleo-
tide change was not specific to any lineage and was
detected in 5 samples.
Figure 1 Nucleotide sequence variations among HPV isolates. Numbering refers to the first nucleotide of the HPV 18 reference genome
(accession number NC001357). Each row indicates the isolate identification and the PCR nucleotide sequence alignment compared to the
reference. Isolates EF202143-EF202155 are HPV 18 known variant sequences which belong to Asian-amerindian lineage, African and European
lineage. Nucleotide positions where a substitution leads to a change of amino acid are highlighted in gray. In the first column, samples that are
highlighted in gray correspond to single HPV infection samples, whereas not highlighted samples correspond to multiple HPV infections. Dashes
indicate absence of nucleotide sequence data. Recombinant variants are indicated by an asterisk.
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In our study, the predominant variant found was the
European (25/44 samples) followed by the African (10/44)
and the Asian-amerindian variants (5/44).
Phylogenetic analysis of the all regions studied showed
that European and Asian-amerindian lineages formed
closely related nodes as well as a maximal nucleotide diver-
sity between African and non-African variants (Figure 2)
(Additional file 1).
Isolates which showed nucleotide diversity from the
three branches (European, Asian-amerindian and African) -
LSM3, LSCM, LSCE, LSMK1, LSCR, LSMH1, LSC5,
LSM7 and LSCB – were analyzed for possible recombina-
tion (Table 1).
Phylogenetic trees were constructed for each
sequenced region from these isolates and we found that
samples LSCR, LSMH1, LSC5 and LSM7 belonged tothe European branch in all regions and therefore, were
classified as Europeans. Isolate LSCB belonged to the
European lineage in all regions but in E6 (Asian-amerindian)
due to the lack of one nucleotide substitution (C549A).
This sample was also classified as European.
Samples LSM3, LSCM, LSCE, LSMK1 belonged to the
African branch in some regions but were classified as
European in others (Table 1).
RDP [15], Maxchi [16] and Chimaera were used for the
detection of recombination in these 9 samples and only 2
of them were found to be recombinant, one single
(LSMK1) and one multiple HPV infection (LCE) (Table 1).
LSCM and LSM3 were classified as X variants (unknown).
Variants, type of lesion and infection type
Out of 44 samples, 32 were classified by pathologists as























































































































































































































































































Figure 2 Phylogenetic tree of the HPV 18 isolates. E6, E7, E4, L1 and URR nucleotide sequences of isolates using the Bayesian inference
method implemented in MrBayes 3.1. Isolates EF202143-EF202155 are included as HPV 18 reference variant sequences which belong to Asian-
amerindian lineage, African and European lineage.
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specimens.
High grade lesions only presented African variants (2/3
isolates, 66.7%) and variants that presented both African
and European substitutions (1/3 isolates, 33.3%) whereasTable 1 Evidence for recombinant samples
Sample \ Gene E6 E7 E4 L1 URR
LSM3 Af Af X X E
LSCE Af Af E E E
LSMK1 AsA E Af E Af
LSCR E E E E E
LSMH1 E E E E E
LSC5 E E E E E
LSM7 E E E E E
LSCB AsA E E E E
LSCM Af E Af Af E
Isolates analyzed for possible recombination. Phylogenetic trees were constructed f
(AsA), European (E) or African (Af) variants. RDP, Maxchi and Chimaera were used fo
of data.most European and Asian-amerindian variants were
detected in negative cytologies (Table 2).
Presence of lesions associated with non-European va-
riants was found to be statistically significant (p = 0.01053).
Nevertheless, there was not a statistically significantProgram inference
No recombination detected.
Maxchi detected recombination.(LSCM is one of the donors)







or each sequenced region and isolates were classified as Asian-amerindian
r the detection of recombination. URR: Upstream regulatory region, X: absence
Table 2 Human papillomavirus 18 variants vs type of
lesion
Variants \ Type of Lesion Neg L-SIL H-SIL
European 71.0% 3.3% 0%
Asian-amerindian 12.9% 1.1% 0%
African 12.9% 4.4% 100%
Recombinant 3.2% 1.1% 0%
Neg: no lesion, L-SIL: low-grade squamous intrapehitelial lesion, H-SIL: high-
grade squamous intraephitelial lesion.
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and presence of lesions (p = 0.18078).Discussion
There are almost no epidemiologic studies about HPV
18 variants carried out in Spain and even though na-
tional HPV prevalence is low, it cannot be forgotten that
this genotype together with genotype 16 cause 70% of
cervical cancer cases.
Many authors confirm that distribution of HPV variants
is related to geographic or race distribution [6,17] and
therefore, Spain should expect predominance of European
variant, followed by African and Asian-amerindian
variants. Our results show concordance with this stating:
25 European variants (56.8%), 10 African (22.7%) and 5
Asian-amerindian variants (11.4%).
HPV 18 has been associated with both recurrent lesions
with very bad clinical prognosis [18] and benign lesions
[19]. This fact may reflect the oncogenic potential differ-
ence among variants. Hecht et al [20] identified a HPV 18
variant with lower oncogenic potential due to its absence
in cervical cancer but presence in 40% of intraepithelial
lesions. Villa et al [21] suggested that non-European HPV
18 variants persisted more frequently and were moreTable 3 Polymerase chain reaction characteristics for Human
Primer sequence (50 – 30) Annealing Te
E6 F AGTAACCGAAAACGGTCGGGA 55°C/40
E6 R GTTGTGAAATCGTCGTTTTTCA
E7 F TGAAAAACGACGATTTCACAAC 55°C/40
E7 R ACCTTCTGGATCAGCCATTG
E4 F GTAAAGGAAGGGTACAACACG 57°C/35
E4 R CTGTCCAATGCCAGGTGGA
LCR 1 F TCGGTTGCCTTTGGCTTAT 55°C/40
LCR 1 R AAGGGTAGACAGAATGTTGGACA 55°C/40
LCR 2 F GCTAATTGCATACTTGGCTTG




*Position numbering refers to the first nucleotide of the HPV 18 reference genomeassociated with pre-invasive lesions. Since then, most
studies confirm that different variants of the same geno-
type differ in their pathogenic characteristics and there-
fore, nucleotide substitutions may play an important role.
Our study results show concordance with these statements
as African variants and variants where most of specific-
african substitutions were detected were the only type of
variants detected in H-SIL.
Most nucleotide changes reported in our study have
been previously described and some of them are of par-
ticular importance. In URR, the mutation A41G is located
in the Sp-1 binding site and isolates with this nucleotide
variation have shown to have an increased transcriptional
activity [22]. Variations in positions 41 and 104 modulate
Sp1 and YY1 activities and are associated to a higher ac-
tivity of the E6/E7 promoter. Patients with T104C substi-
tution are less likely to present tumour recurrence [23].
Other nucleotide changes like T7651C, A7658C and
C7726T also lay within transcription factor binding sites.
Substitutions C287G, C6842G and T7592C were found
in all our isolates. Variation C6842G has been previously
reported as error in the original sequence [24], and H.
Arias–Pulido et al. sequenced the original reference HPV
18 plasmid (provided by E-M de Villiers, Deutsches Krebs-
forschungzentrum, Germany) and observed the substitu-
tion T7592C [25], so it is considered as a sequencing error
in the original HPV 18 reference sequence report.
Furthermore, ten “new” nucleotide variations have
been detected and two of them were non-synonymous
and lead to amino acid changes (T318C and C3617T,
Tir/His and Ser/Leu, respectively).
Knowledge on HPV variants and their nucleotide variabi-
lity is essential for three main reasons: i) nucleotide varia-
tions may interfere with the viral oncogenic potential,
ii) host cellular immune response can be different whenpapillomavirus 18
mp/Cycles Nucleotides amplified* Amplicon size
cycles 38-491 454 pb
cycles 470-931 462 pb
cycles 3309-3792 484 pb
cycles 7465-7775 311 pb
cycles 7718-163 303 pb
cycles 6558-7012 455 pb
(accession number NC001357). F: forward primer, R: reverse primer.
Table 4 GeneBank accession numbers for the sequenced
isolates
Isolate E6 E7 E4 L1 URR
LSM1 JN416211 JN416162 X JN416262 JN416313
LSM2 JN416212 JN416163 JN416121 JN416263 JN416314
LSM3 JN416213 JN416164 X X JN416315
LSM4 JN416214 JN416165 JN416122 JN416264 JN416316
LSC5 JN416215 JN416166 JN416123 JN416265 JN416317
LSM6 JN416216 X X JN416266 JN416318
LSM7 JN416217 JN416167 JN416124 JN416267 JN416319
LSC9 JN416219 JN416169 JN416125 JN416269 JN416321
LSCA JN416220 JN416170 X JN416270 JN416322
LSCB JN416221 JN416171 JN416126 JN416271 JN416323
LSCC JN416222 JN416172 JN416127 JN416272 JN416324
LSCD JN416223 JN416173 X JN416273 JN416325
LSCE JN416224 JN416174 JN416128 JN416274 JN416326
LSCF X X X JN416275 JN416327
LSCG JN416225 JN416175 X JN416276 JN416328
LSCH JN416226 JN416176 JN416129 JN416277 JN416329
LSCI JN416227 JN416177 JN416130 JN416278 JN416330
LSCJ JN416228 JN416178 JN416131 JN416279 JN416331
LSCK JN416229 JN416179 JN416132 JN416280 JN416332
LSCL JN416230 JN416180 JN416133 JN416281 JN416333
LSCM JN416231 JN416181 JN416134 JN416282 JN416334
LSCP JN416232 JN416182 JN416135 JN416283 JN416335
LSCR JN416234 JN416184 JN416137 JN416285 JN416337
LSCS JN416235 X JN416138 JN416286 JN416338
LSCW JN416238 JN416187 JN416141 JN416289 JN416341
LSCX JN416239 JN416188 JN416142 JN416290 JN416342
LSCY JN416240 JN416189 JN416143 JN416291 JN416343
LSCA1 JN416241 JN416190 JN416144 JN416292 JN416344
LSCC1 JN416243 JN416192 JN416146 JN416294 JN416346
LSCE1 JN416245 JN416194 X JN416296 JN416348
LSMF1 JN416246 JN416195 JN416147 JN416297 JN416349
LSMG1 JN416247 JN416196 JN416148 JN416298 JN416350
LSCH1 JN416248 JN416197 JN416149 JN416299 JN416351
LSCI1 JN416249 JN416198 JN416150 JN416300 JN416352
LSCJ1 JN416250 JN416199 JN416151 JN416301 JN416353
LSMK1 JN416251 JN416200 JN416152 JN416302 JN416354
LSML1 JN416252 JN416201 JN416153 JN416303 JN416355
LSCM1 JN416253 JN416202 JN416154 JN416304 JN416356
LSCP1 JN416256 JN416205 JN416157 JN416307 JN416359
LSCQ1 JN416257 JN416206 JN416158 JN416308 JN416360
LSCR1 JN416258 JN416207 JN416159 JN416309 JN416361
LSCS1 JN416259 JN416208 JN416160 JN416310 JN416362
Table 4 GeneBank accession numbers for the sequenced
isolates (Continued)
LSCT1 JN416260 JN416209 X JN416311 JN416363
LSCU1 JN416261 JN416210 JN416161 JN416312 JN416364
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sid which may be relevant for the vaccination, iii) HPV
infections with a variant may not give immunological pro-
tection against a subsequent infection with other variant of
the same genotype.
Nowadays, HPV variants recombination has already
been described and it is more often found since coinfec-
tion with more than one HPV type prevalence is not a
unusual finding [10].
In our study we detected 2 recombinant variants
(4.5%) which might have been missed or wrong classified
if only amplifying one genomic region. Furthermore,
non-recombinant samples as LSCM or LSM3 showed
specific-african substitutions in some regions (for ex-
ample E6) whereas they would be classified as european
variants when only analyzing nucleotide variation in
URR. Therefore, characterizing more than one genomic
region may be essential in order to detect recombination
and classify HPV variants properly.
We amplified URR and E6, E7 and L1genes from at
least 93% of samples. However, when characterizing E4
region, we were only able to amplify 35 samples. E4 gene
is generally disrupted during DNA integration into the
host genome and this disruption may explain the inabil-
ity to amplify E4 gene in some of our samples.
In conclusion, data and knowledge on geographic
HPV intratypic variants distribution might help to estab-
lish a data base about the diversity and pathogenicity of
different HPV variants, which may help to design and




Clinical Microbiology and Infection Control Department
at Basurto University Hospital (Basque Country, North
of Spain) analyzed samples which were remitted from
different Hospital Services, especially the Consultation
of Sexually Transmitted Diseases and the Department of
Obstetrics and Gynecology, from 2007 to 2010.
All samples were collected from patients with clinical
manifestations of HPV related infections. Lesions were
classified by pathologists into three categories: negative
(no lesion was found), low-grade squamous intraepithe-
lial lesion (L-SIL) or high-grade squamous intraepithelial
lesion (H-SIL).
Molecular genotyping was carried out using “Linear
Array HPV Genotyping Test” kit (Roche Molecular
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http://www.virologyj.com/content/9/1/258Diagnostics). In our study, we analyzed positive samples
for HPV genotype 18 (both single infections and multiple
HPV infections) from patients who had given written,
informed consent.
Genomic DNA extraction
DNA extraction was performed by QIAamp DNA mini
Kit (Qiagen, Hilden, Germany), according to the manu-
facturer´s instructions. Extracted DNA was eluted with
200 μl AE buffer and stored at −20°C until amplification.
PCR amplification and sequencing
Amplification of HPV E6, E7, E4 genes and the URR was
performed using type-specific primers designed according
to HPV 18 genome prototype sequence (GenBank acces-
sion number NC001357). The URR was amplified using 2
primer sets. In order to amplify L1 region, consensus HPV
primers were used (Table 3).
PCR was performed in 30 μl of reaction mixture con-
taining 10 × PCR buffer, 25 mmol/L MgCl2, 25 mmol/L
of each deoxynucleoside, 100 pmol/L of sense and anti-
sense primer, 5 μl of template DNA and 2,5 U of Taq
DNA polymerase (Qiagen).
The thermal program started with a pre-heat of 95°C for
15 min, followed by 35–40 cycles of suitable annealing
temperature which depended on the primers and finished
with a final extension at 72°C for 10 min (Table 3).
PCR products were confirmed based on specific bands
of amplified DNA presence in agarose gel (2%). After-
wards, amplimers were automatically sequenced using the
“Big Dye Terminator Cycle Sequencing kit” (Applied Bio-
systems) according to the manufacturer´s instructions.
For E6, E7, E4 and URR amplicons the same forward
specific primers as those used in amplification were
chosen as sequencing primers. In the L1 region, a spe-
cific primer was used in order to sequence HPV 18 and
not other HPV types present in cases of multiple infec-
tion (Table 3).
Nucleotide variations, phylogenetic analysis: variants and
recombination
HPV sequences were aligned and compared to the HPV
18 prototype sequence which belongs to the Asian-
amerindian lineage (accession number NC001357), using
BioEdit Sequence Alignment Editor v7.0.4.1 and Clustal
W (http://www.genome.jp/tools/clustalw/).
Amplification and sequencing of the samples were
repeated to confirm nucleotide variations which were
present in less than three isolates.
Sequences were assigned to a lineage on the basis of their
similarity to HPV 18 known variant sequences [26] which
belong to Asian-amerindian lineage (GenBank accession
numbers: EF202143 - EF202146), African (EF202152 -
EF202155) and European lineage (EF202147- EF202149,EF202151). Phylogenetic trees were built using the
Bayesian inference method implemented in MrBayes 3.1
[27] and three methods (all implemented in RDP3 [15])
were used for the detection of recombination (RDP [15],
Maxchi [16] and Chimaera) to analyze isolates which did
not adjust to the clusters.
Lesions
Association of lesions and variants or infection type (single
HPV vs multiple HPV infection) was analyzed. Fisher exact
test was used for statistically significant association.
GenBank accession numbers
The following are the GenBank accession numbers for all
the sequences used in this analysis. X indicates absence of
nucleotide sequence data Table 4.
Ethical approval
All procedures followed were approved by the appropri-
ate Ethics Commitee related to our institutions (Basurto
University Hospital and University of Basque Country)
and complied with the guidelines and ethical standards
for experimental investigation with human subjects of
Helsinki Declaration of 1975, as revised in 2000. All
study participants provided written, informed consent.
Additional file
Additional file 1: E4, E6, E7, L1, LCR_bay. Phylogenetic trees were
constructed for each region individually.
Abbreviations
HPV: Human papillomavirus; H-SIL: High-grade squamous intraepithelial
lesion; L-SIL: Low-grade squamous intraepithelial lesion; SIL: Squamous
intraepithelial lesion; URR: Upstream regulatory region.
Competing interests
All authors declare no potential conflicts of interest.
Authors’ contributions
LSA carried out the molecular studies, participated in the sequence
alignment and drafted the manuscript. MB and EA participated in the design
of the study and its coordination and have been involved in drafting the
manuscript and revising it critically for important intellectual content. SH, DA
and VE have made substantial contributions to acquisition of samples and
data and have revised the manuscript critically. KGE and BMJ performed
phylogenetic and statistical analysis. RC conceived the study, participated in
its design and coordination and has given final approval of the version to be
published. All authors read and approved the final manuscript.
Acknowledgements
Authors wish to thank the Department of Health from the Basque
Government for supporting this project [project number 2008111058].
Author details
1Immunology, Microbiology and Parasitology Department, University of
Basque Country, Leioa 48940, Spain. 2Clinical Microbiology and Infection
Control Department, Basurto University Hospital, Bilbao 48013, Spain.
3Obstetrics and Gynecology Department, Basurto University Hospital, Bilbao
48013, Spain. 4Genetics, Physical Anthropology and Animal Physiology
Department, University of Basque Country, Leioa 48940, Spain.
Arroyo et al. Virology Journal 2012, 9:258 Page 8 of 8
http://www.virologyj.com/content/9/1/258Received: 4 June 2012 Accepted: 30 October 2012
Published: 2 November 2012References
1. Muñoz N, Castellsague X, de Gonzalez AB, Gissmann L: HPV in the etiology
of human cancer. Vaccine 2006, 24:1–10.
2. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, et al: Human
papillomavirus type distribution in invasive cervical cancer and high-
grade cervical lesions: a meta-analysis update. Int J Cancer 2007,
121:621–632.
3. Muñoz N, Bosch FX, Castellsagué X, Díaz M, de Sanjose S, Hammouda D, et al:
Against which human papillomavirus types shall we vaccinate and screen?
the international perspective. Int J Cancer 2004, 111:278–285.
4. Yamada T, Manos MM, Peto J, Greer CE, Munoz N, Bosch FX, et al: Human
papillomavirus type 16 sequence variation in cervical cancers: a
worldwide perspective. J Virol 1997, 71:2463–2472.
5. Ong CK, Chan SY, Campo MS, Campo MS, Fujinaga K, Mavromara-Nazos P,
et al: Evolution of human papillomavirus type 18: an ancient
phylogenetic root in Africa and intratype diversity reflect coevolution
with human ethnic groups. J Virol 1993, 67:6424–6431.
6. de Araujo Souza PS, Sichero L, Macia PC: HPV variants and HLA
polymorphisms: the role of variability on the risk of cervical cancer.
Future Oncol 2009, 5:359–370.
7. Sichero L, Ferreira S, Trottier H, Duarte-Franco E, Ferenczy A, Franco EL, et al:
High grade cervical lesions are caused preferentially by non-european
variants of HPVs 16 and 18. Int J Cancer 2007, 120:1763–1768.
8. López-Savedra A, González-Maya L, de Ponce León S, García-Carranca A,
Mohar A, Lizano M: Functional implication of sequence variation in the
long control region and E2 gene among human papillomavirus type 18
variants. Arch Virol 2009, 154:747–754.
9. de Villiers EM, Fauquet C, Broker TR, Bernard HU, Zur HH: Classification of
papillomaviruses. Virology 2004, 324:17–27.
10. Angulo M, Carvajal-Rodríguez A: Evidence of recombination within human
alpha-papillomavirus. Virol J 2007, 4:33.
11. Jiang M, Xi LF, Edelstein ZR, Galloway DA, Olsem GJ, Lin WC, et al:
Identification of recombinant human papillomavirus type 16 variants.
Virology 2009, 394:8–11.
12. Méndez F, Muñoz N, Posso H, Molano M, Moreno V, van den Brule AJ, et al:
Cervical coinfection with human papillomavirus (HPV) types and
possible implications for the prevention of cervical cancer by HPV
vaccines. J Infect Dis 2005, 192:1158–1165.
13. Tinelli A, Leo G, Dell’Edera D, Storelli F, Galante MM, Guido M, et al:
Molecular methods for a correct diagnosis of multiple HPV infections
and clinical implications for vaccine. Int J Gynecol Cancer 2011,
21:545–550.
14. Nielson CM, Harris RB, Flores R, Abrahamsen M, Papenfuss MR, Dunne EF, et al:
Multiple-type human papillomavirus infection in male anogenital sites:
prevalence and associated factors. Cancer Epidemiol Biomarkers Prev 2009,
18:1077–1083.
15. Martin DP, Lemey P, Lott M, Moulton V, Posada D, Lefeuvre P: RDP3: a
flexible and fast computer program for analyzing recombination.
Bioinformatics 2010, 26:2462–2463.
16. Smith J: Analyzing the mosaic structure of genes. J Mol Evol 1992,
34:126–129.
17. Xi LF, Kiviat NB, Hildesheim A, Galloway DA, Wheeler CM, Ho J, et al: Human
papillomavirus type 16 and 18 variants: race-related distribution and
persistence. J Natl Cancer Inst 2006, 98:1045–1052.
18. Im SS, Wilczynski SP, Burge RA, Monk BJ: Early stage cervical cancers
containing human papillomavirus type 18 DNA have more nodal
metastasis and deeper stromal invasion. Clin Cancer Res 2003,
9:4145–4150.
19. Burger R, Monk BJ, Kurosaki T, Anton-Culver H, Vasiley SA, Berman ML, et al:
Human papillomavirus type 18: association with poor prognosis in early
stage cancer. J Natl Cancer Inst 1996, 88:1361–1368.
20. Hecht J, Kadish A, Jiang G, Burk R: Genetic characterization of the human
papillomavirus (HPV) 18 E2 gene in clinical specimens suggests the
presence of a subtype with decreased oncogenic potential. Int J Cancer
1995, 60:369–376.
21. Villa LL, Sichero L, Rahal P, Caballero O, Ferenczy A, Rohan T, et al:
Molecular variants of human papillomavirus types 16 and 18preferentially associated with cervical neoplasma. J Gen Virol 2000,
81:2959–2968.
22. Rose B, Steger G, Dong XP, Thompson C, Cossart Y, Tattersall M, et al: Point
mutations in SP1 motifs in the upstream regulatory region of human
papillomavirus type 18 isolates from cervical cancers increase promoter
activity. J Gen Virol 1998, 79:1659–1663.
23. Rose B, Thompson CH, Zhang J, Stoeter M, Stephen A, Pfister H, et al:
Sequence variation in the upstream regulatory region of HPV 18 isolates
from cervical cancers. Gynecol Oncol 1997, 66:282–289.
24. Meissner J: Sequencing errors in reference HPV clones. In Human
papillomaviruses. A compilation and analysis of nucleic acid and amino acid
sequences. 3rd edition. Edited by Myers G, Baker C, Munger K, et al. Los
Alamos (NM): Theoretical Biology and Biophysics, Los Alamos National
Laboratory; 1997:110–123.
25. Arias-Pulido H, Peyton CL, Torrez-Martinez N, Anderson DN, Wheeler CM:
Human papillomavirus type 18 variant lineages in United States
populations characterized by sequence analysis of LCR-E6, E2, and L1
regions. Virology 2005, 338:22–34.
26. Chen Z, DeSalle R, Schiffmn M, Herrero R, Burk RD: Evolutionary dynamics
of variant genomes of human papillomavirus types 18, 45 and 97. J Virol
2009, 83:1443–1455.
27. Ronquist F, Huelsenbeck JP: MrBayes 3: Bayesian phylogenetic inference
under mixed models. Bioinformatics 2003, 19:1572–1574.
doi:10.1186/1743-422X-9-258
Cite this article as: Arroyo et al.: Human Papillomavirus (HPV) genotype
18 variants in patients with clinical manifestations of HPV related
infections in Bilbao, Spain. Virology Journal 2012 9:258.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
